Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea

EU orphan designation number: EU/3/11/915   
Active ingredient: 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea
Indication: Treatment of acute myeloid leukaemia
Sponsor: AbbVie Ltd
Maidenhead, SL6 4XE, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
31/10/2011 Centralised Orphan - Designation EMA/OD/067/11 (2011)7893 of 27/10/2011
01/02/2013 Centralised Orphan - Transfer of orphan designation EMA/OD/067/11/T/01 (2013)599 of 30/01/2013